


CLINICAL TRIALS » TB DRUG TRIALS



Filter By Keyword

Filter By Attributes

 Pediatric

 Pediatric

 MDR

 HIV/TB

Filter By Country

Filter By Sponsor

Filter By Network

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))

Status: **Completed**

[View Details](#)

A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) ([NCT00523926](#))

Status: **Completed**

[View Details](#)

Last Verified	Acronym	Type	Agent / Regimen	Sponsors	Study Chair / Lead
04/12/10	TMC207-C202	RX	Drug: OPC-67683 (total daily dose of OPC-67683 is 200 mg) for 56 days; Drug: OPC-67683 (total daily dose of OPC-67683 is 400 mg) 56 days; Drug: Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc	Charles D. Wells, M.D.

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))

Status: **Completed**

[View Details](#)

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))

Status: **Completed**

[View Details](#)